Previous Close | 0.1200 |
Open | 0.1300 |
Bid | 0.1300 x 0 |
Ask | 0.1350 x 0 |
Day's Range | 0.1300 - 0.1350 |
52 Week Range | 0.0800 - 0.2800 |
Volume | |
Avg. Volume | 101,446 |
Market Cap | 90.668M |
Beta (5Y Monthly) | 13.07 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0030 |
Earnings Date | Jun 29, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
HALIFAX, Nova Scotia, June 29, 2022 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended April 30, 2022. Profit and Loss Highlights Revenue: The Company recorded revenues in Q3 FY2022 of $323,925 compared to $64,631 for the same period last year. The increase in revenue in comparison with Q3 FY2021 was due to higher sales in for its Miriad®, Multiplo® and Reveal® product lines.Gross Profit: The Company recorded a gross profit in Q3
HALIFAX, Nova Scotia, June 06, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of a U.S. patent (number 11,353,450) for their new innovative and quantitative test system. Through this new patent, MedMira is to further diversify its patent portfolio and expand on its Rapid Vertical Flow Technology® (RVF) based diagnostic tests. This is a step forward in empowering the Company’s strategic vision by offering a rapid multiplexed quantitative diagnostic system
HALIFAX, Nova Scotia, May 27, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on its regulatory progress in Europe and any market accepting the CE mark. MedMira has received the CE mark for three products in 2022 and has four additional applications currently pending with the regulatory body. As of today, the Company has been informed that all applications have been accepted and will be forwarded to the Competent Authority for final CE marking. The Company a